Clik here to view.
NantHealth and Asia Genomics Announce Global Expansion of GPS CancerTM in...
CULVER CITY, Calif. & SINGAPORE NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, announced that it has entered into an agreement for GPS...
View ArticleClik here to view.
CORRECTING and REPLACING KYOCERA Begins Research in AI-based Image...
KYOTO, Japan Fifth paragraph, first sentence of release dated August 29, 2017, should read: The project benefits from a database of more than 20,000 clinical images… (instead of The project benefits...
View ArticleClik here to view.
BioMarker Strategies Announces Two New Patents Granted in Japan, Covering the...
ROCKVILLE, Md. BioMarker Strategies, LLC, today announced that the Japan Patent Office has granted new patents covering the Company’s SnapPath® Cancer Diagnostics System technology and its PathMAP®...
View ArticleClik here to view.
Yamaha Motor Releases the Cell Picking & Imaging System CELL HANDLER(TM)
IWATA, Japan Yamaha Motor Co., Ltd. (TOKYO:7272) (ISIN:JP3942800008) announced today that it has developed the cell picking/imaging system CELL HANDLERTM. This device performs part of the testing...
View ArticleClik here to view.
Shionogi Inc. and Purdue Pharma L.P. to Present Data from Naldemedine Studies...
OSAKA, Japan & FLORHAM PARK, N.J. & STAMFORD, Conn. Purdue Pharma L.P. and Shionogi Inc. will present results from four research studies of naldemedine during the 11th Annual PAINWeek®...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Limited to Present at the Morgan Stanley Annual...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will be present at the Morgan Stanley 15th Annual Global...
View ArticleClik here to view.
Aurigene, a Wholly Owned Subsidiary of Dr. Reddy’s, and Curis Announce CA-170...
BANGALORE, India Aurigene Discovery Technologies Limited, a wholly owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and a specialized biotechnology company...
View ArticleClik here to view.
Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER...
NEW YORK & TOKYO Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the Phase 3 PROSPER trial evaluating XTANDI®...
View ArticleClik here to view.
H3 Biomedicine to Present New Data on H3B-6527, an FGFR4 Inhibitor, at the...
CAMBRIDGE, Mass. H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global...
View ArticleClik here to view.
Samsung Bioepis First to Receive Positive CHMP Opinion on a Trastuzumab...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on...
View ArticleClik here to view.
Arcus Biosciences Announces Option and License Agreement with Taiho...
HAYWARD, Calif. Arcus Biosciences, a US-based biotechnology company focused on the discovery and development of innovative cancer immunotherapies, announced today that it has entered into an option...
View ArticleClik here to view.
Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride...
WOODCLIFF LAKE, N.J. & TOKYO Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (“Eagle” or “the Company”) and SymBio Pharmaceuticals Limited (“SymBio”) (Tokyo Stock Exchange/JASDAQ 4582) today announced...
View ArticleClik here to view.
Sun Pharma Odomzo® (Sonidegib) New Label Approval Shows Sustained Duration of...
MUMBAI, India Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries or associate companies) today announced...
View ArticleClik here to view.
Exelixis Provides Update on Collaborator Daiichi Sankyo’s Phase 3 Clinical...
SOUTH SAN FRANCISCO, Calif. Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has reported positive top-line results from a phase 3...
View ArticleClik here to view.
Konica Minolta Accelerates Expansion of Precision Medicine Business Through...
TOKYO & BOSTON Konica Minolta, Inc. (“Konica Minolta”) (TOKYO: 4902; ISIN: JP3300600008) and Boston-based Invicro LLC (“Invicro”) today announced that they have concluded an agreement whereby...
View ArticleClik here to view.
Takeda to Feature ALUNBRIG™ (brigatinib) Data from Pivotal Phase 2 ALTA Trial...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the company will present four company-sponsored abstracts, including one oral presentation,...
View ArticleClik here to view.
Spectrum Pharmaceuticals Highlights Poziotinib Data in Lung Cancer to be...
HENDERSON, Nev. Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and...
View ArticleClik here to view.
武田在第18届世界肺癌大会上呈报通过枢纽性2期ALTA 临床试验获得的ALUNBRIG™ (brigatinib)数据
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE: 4502)今天宣布，该公司将在国际肺癌研究协会(IASLC)的第18届世界肺癌大会(WCLC)上呈报4篇由公司资助的研究摘要，其中包括一场口头报告，本届大会将于10月15-18日在日本横滨召开。本届会议上的报告将突出强调武田在开发ALUNBRIGTM...
View ArticleClik here to view.
武田薬品、第18回世界肺がん学会議でピボタル第2相ALTA試験から得たALUNBRIG™（ブリガチニブ）のデータを発表へ
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:...
View ArticleClik here to view.
Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term...
BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan Seattle Genetics, Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced final data from the ADCETRIS...
View Article